Skip to content
‹ Back to IndustriesHealthcare

J&J Vaccine Highlights the Desire for Simplicity and Speed in Healthcare

Johnson & Johnson’s Covid-19 vaccine is safe and 72% effective in a U.S. clinical trial, Food and Drug Administration staff said. Watch above or read part of the interview below for Bloomberg Intelligence’s Sam Fazeli thoughts on the simplicity and efficiency implications of the Johnson & Johnson Covid-19 vaccine. — Host: Sam, in the heart…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
J&J Vaccine Highlights the Desire for Simplicity and Speed in Healthcare

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Johnson & Johnson’s Covid-19 vaccine is safe and 72% effective in a U.S. clinical trial, Food and Drug Administration staff said. Watch above or read part of the interview below for Bloomberg Intelligence’s Sam Fazeli thoughts on the simplicity and efficiency implications of the Johnson & Johnson Covid-19 vaccine.

—

Host: Sam, in the heart of the matter, this is a search for simplicity. Peter Hotez of Baylor makes it very clear what we need globally is a simplicity of vaccine delivery. Does J&J accomplish that?

Fazeli: So I don’t think you can get simpler than the J&J vaccine. It needs very basic refrigeration and it’s one dose. So absolutely.

Host: When could we actually see it getting rolled out in the United states?

Fazeli: I think the dates that I’ve been hearing is in the next month or two, they did have some manufacturing issues, but certainly picking up rapidly going into the second half. So but let’s not forget that this vaccine, you know, the US has enough Moderna and Pfizer vaccines now to cover the entirety of the population, at least ordered. So this is a vaccine that really could make a difference to the rest of the world.

Host: Let me ask you the question that I’ve asked all of our esteemed guests in virology, which is from where you sit, Sam, do you look at the better statistics as an extrapolation forward into the spring of this year? Can you extrapolate to an optimistic outcome?

Fazeli: Tom, as you know, I would love to because it’s also my life. But but I am always wary of these variants that are circling. And I would love to think that they are not going to make a difference. And if you look at some countries where they have the B117 variant that was first identified in the UK, they’ve managed to get it under control with lockdown measures. So if we are careful, we can keep it under control. If we’re not. And we go into big gatherings, et cetera. I think there’s a risk that we might have another wave.

*Bloomberg contributed to this article

—

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Four software renewal questions to help get HbA1c to the dental chair

Four software renewal questions to help get HbA1c to the dental chair

Dr. Deepashree Rajendraprasad, a dentist turned hospital business intelligence developer, gives dental practices four questions for software vendors at contract renewal. They cover HL7 FHIR APIs, health information exchange access, SNODENT terminology and electronic referrals. The standards already exist. The payoff shows up chairside in anticoagulant screening, diabetes-guided periodontal care and bisphosphonate surgical planning.

  • 01The HbA1c a dentist asks a patient to remember already sits as a structured field in a hospital data warehouse; getting it to the chair starts with what a practice asks its software vendor.
  • 02Two of the five FHIR resources most relevant to dentistry, Patient and Observation, belong to the normative core of FHIR Release 4, where future changes are meant to stay backward compatible.
  • 03At renewal, ask vendors specifics: which FHIR resources they expose, whether they can query the regional HIE, whether they code in SNODENT, and whether they support structured referrals.

Nov 18, 2026

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

A Google Cloud survey found that only 30% of healthcare organizations have scaled advanced or agentic AI across their operations. Johns Hopkins professor Ritu Agarwal says health systems need a measured baseline, clinician-led workflow design and representative data before they scale. Small pilots hide the rest.

  • 01A 200-person pilot answers whether a tool works; how it behaves on another hospital's patients and what it costs at full volume mostly show up after the pilot ends.
  • 02Just 30% of healthcare organizations said they’ve scaled advanced or agentic AI across operations, according to a Google Cloud survey of 250+ healthcare executives.
  • 03The sharper pre-pilot question: which disease condition, which baseline metric and what projected cost at full volume will this tool be judged against?

Nov 18, 2026

Sterile processing deviations become the norm without stop-and-document rules

Sterile processing deviations become the norm without stop-and-document rules

Advanced Sterilization Products' Tamara Beeler told Censis Technologies' CtUC 2026 audience that sterile processing deviations harden into norms when departments don’t stop, escalate and document them. She connects ANSI/AAMI ST108:2023 water categories, daily cleaning verification, loaner-tray refusal when sets arrive late or lack IFUs, and root cause analysis when rework repeats on the same device.

  • 01ANSI/AAMI ST108:2023 turned water quality for instrument reprocessing into an enforceable standard; AAMI's earlier TIR34 was guidance with no enforcement behind it.
  • 02Some facilities require loaner trays 48 hours before a case, and ASP's Tamara Beeler says a technician at any level can refuse one that arrives late, undocumented or dirty.
  • 03Rework that returns on the same device is the point at which Beeler wants a root cause analysis opened, with the record kept in the instrument tracking system.

Nov 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512